A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
For more information please visit: https://clinicaltrials.gov/study/NCT06103864?term=D7630C00001&rank=1
コメント